Abstract
SUMMERY The patient with diagnosis of idiopathic pulmonary hypertension, functional class III (WHO) was treated by anticoagulants, diuretics. After 6 months of treatment with phosphodiesterase type 5-inhibitor sildenafil, there was observed the negative dynamic with systolic pulmonary arterial pressure, intolerance to exercises. The treatment goals were not achieved with sildenafil therapy. The transitioning from sildenafil to riociguat therapy was done. By 6 months of the riociguat therapy there was achieved the significant improvement of the functional and hemodynamic status. Ам^^ to the stratification risk scale the treatment goals were reached. Keywords: idiopathic pulmonary hypertension, phosphodiester-ase type 5 inhibitor, sildenafil, soluble guanylate cyclase stimulators, riociguat, risk assessment.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
